The Merck & Co drug’s failure in small-cell lung cancer prompts a theory and leaves the way clear for Roche and Astrazeneca.
An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.
A surprisingly successful study of Opdivo and Yervoy suggests that the enrolment of co-called hyperprogressors could have scuppered other trials.
Pharmamar says the US FDA has given an accelerated approval filing plan its blessing, and that means a regulatory submission this year.
A low-key lung cancer readout approaches for United Therapeutics’ Unituxin, while Biogen hopes to buck the tau trend.
Merck & Co faces two US FDA decisions in June, and neither is an obvious guarantee of success.
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
When the World Congress on Lung Cancer kicks off in Toronto later this month all eyes will be on Roche’s Impower-133 study.